Recursion Pharmaceuticals, Inc. (RXRX) Balance Sheet

The reduction in cash rather than a rise in liabilities suggests the balance sheet is weakening through operating burn rather than through leverage. Equity has contracted from about $1.1B to $905.8M over the same span, which is consistent with accumulated losses flowing through retained earnings, now at -$2.4B. Investors should monitor whether the rate of cash decline moderates as collaboration revenue grows.

Debt has remained in a narrow $62M to $108M band across recent quarters, which points to a conservatively structured capital base rather than debt-funded growth. Because the company's liabilities of $315.9M are not dominated by borrowings, the financing question appears to rest on equity and cash reserves rather than refinancing risk. Analysts should still examine the maturity profile of this debt, which is not provided in the supplied data.

A current ratio above 5 indicates that short-term obligations are well covered by current assets, which supports near-term solvency. However, the quarterly cash decline of roughly $77.8M in free cash flow implies a finite runway at the current burn pace, making liquidity a function of future financing as much as current resources. The strength of the ratio should therefore be read as a snapshot of current coverage rather than a measure of sustainable self-funding.

Deferred revenue is a partial proxy for contracted future revenue, and its steady decline across recent quarters suggests that upfront partner payments are being recognized faster than new ones are booked. This warrants caution, since the company's revenue depends on milestone timing that is not captured in the balance sheet. Remaining performance obligations are not included in the supplied data, so forward visibility cannot be fully assessed.